ID: ALA3304438

Max Phase: Preclinical

Molecular Formula: C21H29N3O4

Molecular Weight: 387.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1

Standard InChI:  InChI=1S/C21H29N3O4/c1-14(2)18-12-17(28-23-18)13-22-21(25)15-5-6-19(26-4)20(11-15)27-16-7-9-24(3)10-8-16/h5-6,11-12,14,16H,7-10,13H2,1-4H3,(H,22,25)

Standard InChI Key:  WBLVOWHFRUAMCP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 387.48

Molecular Weight (Monoisotopic): 387.2158

AlogP: 3.21

#Rotatable Bonds: 7

Polar Surface Area: 76.83

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.40

CX LogP: 2.14

CX LogD: 1.10

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.79

Np Likeness Score: -1.10

References

1. Bollinger SR, Engers DW, Ennis EA, Wright J, Locuson CW, Lindsley CW, Blakely RD, Hopkins CR..  (2015)  Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.,  25  (8): [PMID:25801932] [10.1016/j.bmcl.2015.02.058]

2. Bertron JL, Ennis EA, Tarr CJ, Wright J, Dickerson JW, Locuson CW, Blobaum AL, Rook JM, Blakely RD, Lindsley CW..  (2016)  Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.,  26  (19): [PMID:27575469] [10.1016/j.bmcl.2016.08.062]

Source

Source(1):

• Scientific Literature